XOMA XOMA Royalty Corp

8-K Current Report

Filed: March 2, 2026

Health Care

Pharmaceutical Preparations

XOMA Royalty Corp (XOMA) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q-period earnings context in updated corporate presentation, pages 10-11 — see Exhibit for key financial figures
• XOMA operates as a royalty aggregator on biotech/pharma milestone and royalty streams — presentation likely highlights portfolio activity or cash flow updates

Item 7.01 · Regulation FD Disclosure

• Updated corporate presentation published March 2, 2026, filed as Exhibit 99.1
• Reg FD disclosure ensures all investors receive simultaneous access to the same strategic/operational update

Other XOMA Royalty Corp 8-K Filings

8-K Mar 18, 2026

Get deeper insights on XOMA Royalty Corp

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.